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Abstract—The effect of the i.c.v. administration of antisense
oligodeoxynucleotides directed against the  subunit of dif-
ferent Gi-proteins (anti-Gi1, anti-Gi2, anti-Gi3, anti-Go1,
anti-Go2) on the amnesia induced by the H1-antihistamine
diphenhydramine (20 mg kg1 s.c.) was evaluated in the
mouse passive avoidance test. Pretreatment with anti-Gi1
(12.5–25 g per mouse i.c.v.) and anti-Gi2 (25 g per mouse
i.c.v.), administered 24 and 18 h before test, prevented anti-
histamine-induced amnesia. By contrast, pretreatment with
an anti-Gi3 (25 g per mouse i.c.v.), anti-Go1 (25 g per
mouse i.c.v.) and anti-Go2 (25 g per mouse i.c.v.) did not
modify the detrimental effect induced by diphenhydramine.
At the highest effective doses, none of the compounds used
impaired motor coordination, as revealed by the rota rod test,
nor modified spontaneous motility and inspection activity, as
revealed by the hole board test.
These results suggest the important role played by the
Gi1- and Gi2-protein pathway in the transduction mechanism
involved in the impairment of memory processes produced
by the H1-antihistamine diphenhydramine. © 2003 IBRO. Pub-
lished by Elsevier Ltd. All rights reserved.
Key words: Gi-proteins, memory, amnesia,
H1-antihistamines, diphenhydramine, passive avoidance.
The H1-receptor antagonists are amongst the most widely
used medications in the world. These compounds produce
the inhibition of the effects of histamine mediated by H1
receptors such as smooth-muscle contraction in the respi-
ratory and gastrointestinal tracts, pruritus, sneezing by
sensory-nerve stimulation, vasodilation (Simons and Si-
mons, 1994). Therefore, their most common use is in the
treatment of allergic disorders (Rimmer and Church,
1990). In addition to these well-known peripheral effects,
H1-receptor antagonists produce various central inhibitory
actions (Simons and Simons, 1994). The first generation of
H1 antagonists can both stimulate and depress the CNS.
Stimulation occasionally is encountered in patients given
therapeutic doses, but it is a striking feature of poisoning,
which can result in convulsions, particularly in infants
(Faingold and Berry, 1972). Central depression, on the
other hand, usually accompanies therapeutic doses of the
H1 antagonists, which appears to be related to occupancy
of cerebral H1 receptors (Simons and Simons, 1994). Di-
minished alertness, slowed reaction times or somnolence
are common manifestations (Simons and Simons, 1994).
Several data also indicate the induction of an impairment
of cognitive functions by antihistamines. The post-training
i.c.v. administration of histamine has been reported to
cause memory facilitation in rats which is antagonized by
the simultaneous treatment with both promethazine and
cimetidine (de Almeida and Izquierdo, 1986, 1988). More-
over, the administration of diphenhydramine further re-
duces learning ability in patients with seasonal allergic
rhinitis in which learning performances are already im-
paired by allergy symptoms (Vuurman et al., 1996).
Even if the amnesic properties of antihistamines are
documented, the post-receptorial mechanism involved
in the induction of this detrimental effect on cognitive
processes has not yet been established. It has been
reported that first-generation H1-receptor antagonists
are receptor-independent G-protein activators in HL-60
cells, basophils and mast cells (Burde et al., 1996).
Recently, it has been reported that one of the central
effects induced by H1-receptor antagonists, the antino-
ciception, underlies the activation of a signal transduc-
tion mechanism operated by Gi-proteins. The i.c.v. ad-
ministration of pertussis toxin (PTX), compound which
selectively inactivates Gi proteins, prevented the in-
crease of the pain threshold induced by diphenhydra-
mine, pyrilamine and promethazine in the mouse hot-
plate test (Galeotti et al., 1996, 1999). Furthermore, the
i.c.v. administration of antisense oligodeoxynucleotides
directed against the  subunit of different Gi-proteins
(anti-Gi1, anti-Gi2, anti-Gi3) prevented the antinoci-
ception induced by antihistamines (Galeotti et al., 2002).
Since Gi-proteins represent the most widespread mod-
ulatory signalling pathway in neurones (Holz et al.,
1986), we thought it worthwhile to investigate the in-
volvement of Gi proteins into the mechanism of action of
the antihistamine diphenhydramine, by means of an an-
tisense strategy. The Gi protein family is composed by
several subtypes, named Gi1, Gi2, Gi3, Go1 and Go2
(Simon et al., 1991). In the current study we used anti-
sense oligonucleotides (aODN) against the  subunits of
the Gi1, Gi2, Gi3, Go1 and Go2 proteins in order to
determine the role of each subtype in the memory im-
pairment induced by diphenhydramine in a mouse pas-
sive avoidance paradigm. In order to exclude that the
effects produced by aODN treatments were due to the
induction of side effects, some additional behavioural
tests (rota rod, hole board) were performed.
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EXPERIMENTAL PROCEDURES
Animals
Male Swiss albino mice (23–30 g) from the Morini (San Polo
d’Enza, Italy) breeding farm were used. Fifteen mice were housed
per cage. The cages were placed in the experimental room 24 h
before the test for acclimatization. The animals were fed a stan-
dard laboratory diet and tap water ad libitum and kept at 231 °C
with a 12-h light/dark cycle, light on at 7:00 a.m. All experiments
were carried out in accordance with the European Communities
Council Directive of 24 November 1986 (86/609/EEC) for experi-
mental animal care. All efforts were made to minimise the number
of animals used and their suffering.
I.c.v. injection technique
I.c.v. administration was performed under ether anesthesia, ac-
cording to the method described by Haley and McCormick (1957).
Briefly, during anesthesia, mice were grasped firmly by the loose
skin behind the head. A 0.4 mm external diameter hypodermic
needle attached to a 10 l syringe was inserted perpendicularly
through the skull and no more than 2 mm into the brain of the
mouse, where 5 l were then administered. The injection site was
1 mm to the right or left from the midpoint on a line drawn through
to the anterior base of the ears. Injections were performed into the
right or left ventricle, randomly. To ascertain that the drugs were
administered exactly into the cerebral ventricle, some mice (20%)
were injected with 5 l of diluted 1:10 India ink and their brains
examined macroscopically after sectioning. The accuracy of the
injection technique was evaluated and the percentage of correct
injections was 95.
Passive-avoidance test
The test was performed according to the step-through method
described by Jarvik and Kopp (1967). The apparatus consisted of
a two-compartment acrylic box with a lighted compartment con-
nected to a darkened one by a guillotine door. As soon as the
mouse entered the dark compartment, it received a punishing
electrical shock (0.5 mA, 1 s). The latency times for entering the
dark compartment were measured in the training test and after
24 h in the retention test. The maximum entry latency allowed in
the training and retention sessions was, respectively, 60 and
180 s. In this test, diphenhydramine (20 mg kg1) was i.p. injected
immediately after the training session, whereas aODNs (6.5–
25 g per mouse) were i.c.v. injected 24 and 18 h before training.
Between 11 and 25 mice were tested.
Hole board test
The hole board test was performed according to Galeotti et al.
(2002). The test consisted of a 40 cm square plane with 16
flush-mounted cylindrical holes (3 cm diameter) distributed four by
four in an equidistant, grid-like manner. Mice were placed on the
centre of the board one by one and allowed to move about freely
for a period of 10 min each. Two electric eyes, crossing the plane
from mid-point to mid-point of opposite sides, thus dividing the
plane into four equal quadrants, automatically signalled the move-
ment of the animal (counts in 5 min) on the surface of the plane
(locomotor activity). Miniature photoelectric cells, in each of the 16
holes, recorded (counts in 5 min) the exploration of the holes
(exploratory activity) by the mice. The test was performed 18 h
after the last i.c.v. injection of degenerate ODN (dODN; 25 g per
mouse) or aODN (25 g per mouse). Twelve mice per group were
tested.
Rota rod test
The apparatus consisted of a base platform and a rotating rod with
a diameter of 3 cm and a non-slippery surface. The rod was
placed at a height of 15 cm from the base. The rod, 30 cm in
length, was divided into five equal sections by six disks. Thus, up
to five mice were tested simultaneously on the apparatus, with a
rod-rotating speed of 16 r.p.m. The integrity of motor coordination
was assessed on the basis of the number of falls from the rod in
30 s according to Vaught et al. (1985). Those mice scoring less
than three and more than six falls in the pretest were rejected
(20%). The performance time was measured before (pretest) and
15, 30 and 45 min after the beginning of the test. Animals were
i.c.v. pretreated 24 and 18 h prior to the test with dODN (25 g per
mouse) or aODN (12.5–25 g per mouse). Twelve mice per group
were tested.
aODN
Phosphodiester oligonucleotides (ODNs) protected from terminal
phosphorothioate double substitution (capped ODNs) against
possible exonuclease-mediated degradation were purchased by
Tib Molbiol (Genoa, Italy). The sequences of the 33-mer aODNs
used in the present study were the following: anti-Gi1: 5-G*C*T
GTC CTT CCA CAG TCT CTT TAT GAC GCC G*G*C-3; anti-
Gi2: 5-A*T*G GTC AGC CCA GAG CCT CCG GAT GAC GCC
C*G*A-3; anti-Gi3: 5-G*C*C ATC TCG CCA TAA ACG TTT
AAT CAC GCC T*G*C-3; anti-Go1: 5- A*G*G CAG CTG CAT
CTT CAT AGG TG*T *T -3; anti-Go2: 5-G*A*G CCA CAG CTT
CTG TGA AGG CA*C *T -3. All ODNs were previously charac-
terised by in vitro (immunoblotting) and in vivo (tail flick) experi-
ments (Kleuss et al., 1991; Raffa et al., 1994; Sanchez-Blazquez
et al., 1995; Sanchez-Blazquez and Garzon, 1998). We also
confirmed the aODN effect on Gi/o protein levels by performing
immunoblotting experiments. We observed a statistically signifi-
cant reduction of the expression of Gi1 (36.410.6), Gi2
(38.913.6), Gi3 (41.16.9), Go1 (39.811.1), Go2
(37.112.5) levels after aODN treatment (25 g per mouse i.c.v.)
in comparison with mice treated with dODN (25 g per mouse
i.c.v.). The dODN treatment did not modify the G protein levels in
comparison with saline-treated mice. At the dose of 6.5 g per
mouse i.c.v., we did not observe any significant modification of the
protein levels (data not shown). A 33-mer fully dODN 5-N*N*N
NNN NNN NNN NNN NNN NNN NNN NNN NNN N*N*N-3
(where N is G, or C, or A, or T) and a 25-mer fully dODN 5-N*N*N
NNN NNN NNN NNN NNN NNN NN*N *N-3 (where N is G, or C,
or A, or T) were used as a control respectively for anti-Gi and
anti-Go. ODNs were vehiculated intracellularly by an artificial
cationic lipid (DOTAP; Sigma, Milan, Italy) to enhance both uptake
and stability, as described previously (Capaccioli et al., 1993).
aODN or dODN were preincubated at 37 °C for 30 min with 13 M
DOTAP and supplied to mice by i.c.v. injection of 5 l solution 18
and 24 h prior to the behavioural tests.
Drugs
The following drugs were used: diphenhydramine hydrochloride,
D-amphetamine hydrochloride (De Angeli). Drugs were dissolved
in isotonic (NaCl 0.9%) saline solution. Drug and ODNs concen-
trations were prepared in such a way that the necessary dose
could be administered in a volume of 5 l by i.c.v. injection or
10 ml kg1 by s.c. administration.
Statistical analysis
All experimental results are given as the meanS.E.M. Analysis
of variance, followed by Fisher’s protected least significant differ-
ence procedure for post hoc comparison, was used to verify
significance between two means. Data were analysed with the
StatView software for the Macintosh (1992). P values of 0.05
were considered significant.
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RESULTS
Effect of aODN against Gi subunits on
diphenhydramine amnesia
Diphenhydramine (20 mg kg1 s.c.) induced amnesia in
the mouse passive avoidance test that was prevented by
pretreatment with an aODN against the  subunit of the Gi1
proteins. Anti-Gi1 (6.25–12.5 g per mouse i.c.v.) pro-
duced a dose-dependent antagonism of the detrimental
effect produced by the H1-antihistamine. The dose of
6.25 g per mouse i.c.v. was completely ineffective;
12.5 g per mouse i.c.v. partially prevented diphenhydra-
mine amnesia whilst the doses of 25 g per mouse i.c.v.
enhanced the entrance latency in the retention session up
to a value comparable to that produced by control animals
(Fig. 1).
The administration of an aODN against the  subunit of
the Gi2 proteins (6.25–25 g per mouse i.c.v.), dose-
dependently prevented diphenhydramine-induced amne-
sia. At the concentration of 25 g per mouse i.c.v., a
complete prevention was obtained, at the dose of 12.5 g
partially prevented diphenhydramine amnesia, even if the
statistical significance was not reached, whereas, at
6.25 g per mouse i.c.v., the aODN pretreatment was
ineffective (Fig. 2).
The administration of an aODN against the  subunit of
the Gi3 proteins (12.5–25 g per mouse i.c.v.), in contrast
to anti-Gi1 and anti-Gi2, was unable to prevent diphen-
hydramine-induced amnesia (Fig. 3). At the highest dose
employed, anti-Gi2 did not modify the entrance latency in
mice in comparison with the control groups (Fig. 3).
A time-course of recovery from antihistamine amnesia
after aODN treatment was performed. The prevention of
diphenhydramine-induced impairment of memory pro-
cesses produced by anti-Gi1 and anti-Gi2 at the highest
active dose (12.5–25 g per mouse i.c.v.), disappeared 7
days after the end of the aODN pretreatment (data not
shown).
Effect of aODN against Go subunits on
diphenhydramine amnesia
The administration of an aODN against the  subunit of the
Go1 and Go2 proteins (25 g per mouse i.c.v.) was unable
to prevent diphenhydramine-induced amnesia (Fig. 4). At
the highest dose employed, anti-Gi2 did not modify the
entrance latency in mice in comparison with the control
groups (Fig. 4).
Effect of diphenhydramine on mouse behaviour
Diphenhydramine, at the dose used in the present work,
elicited its detrimental effect on memory functions without
changing gross behaviour of mice. The H1-antihistamine
investigated did not alter the mice motor coordination, as
revealed by the rota rod test, the spontaneous motility and
inspection activity, as revealed by the hole board test (data
not shown).
Effect of aODNs on mouse behaviour
The motor coordination of mice pretreated with aODN to
Gi1 (25 g per mouse i.c.v.), Gi2 (25 g per mouse
i.c.v.), Gi3 (25 g per mouse i.c.v.), Go1 (25 g per
mouse i.c.v.) and Gi2 (25 g per mouse i.c.v.), was
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Fig. 1. Prevention by aODN against the  subunit of Gi1 protein (6.25–25 g per mouse i.c.v.) of diphenhydramine (20 mg kg
1 s.c.) amnesia in the
mouse passive avoidance test. Vertical lines represent S.E.M. * P0.05, ** P0.01 in comparison with dODNdiphenhydramine-treated mice.
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evaluated by using the rota rod test. The motor coordina-
tion of aODN-treated groups was not impaired when com-
pared with that of dODN-treated mice (Fig. 5).
The spontaneous motility and exploratory activity of
mice was not modified by administration of the above-
mentioned aODNs as revealed by the hole-board test in
comparison with dODN-treated mice (Fig. 6). In the same
experimental conditions D-amphetamine (1 mg kg1 i.p.),
used as the reference drug, increased both parameters
evaluated (Fig. 6).
0
20
40
60
80
100
120
140
160
180
training
retention
la
te
nc
y 
to
 e
nt
er
 th
e 
da
rk
 c
om
pa
rtm
en
t (
s) 
    
   
diphenhydramine 20 mg kg-1 i.p.
**
saline
6.25 12.5 25anti-Gi 2α 25
25dODN 25
Fig. 2. Prevention by aODN against the  subunit of Gi2 protein (6.25–25 g per mouse i.c.v.) of diphenhydramine (20 mg kg
1 s.c.) amnesia in the
mouse passive avoidance test. Vertical lines represent S.E.M. ** P0.01 in comparison with dODNdiphenhydramine-treated mice.
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Fig. 3. Lack of effect by aODN against the  subunit of Gi3 protein (12.5–25 g per mouse i.c.v.) of diphenhydramine (20 mg kg
1 s.c.) amnesia in
the mouse passive avoidance test. Vertical lines represent S.E.M. * P0.05, ** P0.01 in comparison with dODNsaline-treated mice.
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DISCUSSION
The important role played by the Gi-protein family in the
mechanism of amnesic action of diphenhydramine is indi-
cated by present results. The inhibition of the expression of
Gi1 and Gi2 produced a dose-dependent prevention of
diphenhydramine-induced amnesia whereas the adminis-
tration of aODNs against Gi3, Go1 and Go2 never
exerted any modification of diphenhydramine activity in the
mouse passive avoidance test. These results indicate a
differential involvement of the Gi protein subtypes in the
mechanism of action of the investigated H1-antihistamine.
In particular, the integrity and functionality of Gi1 and Gi2
proteins appears essential to produce memory impairment
by diphenhydramine. By contrast, the Gi3, Go1 and
Go2 subtypes, in these experimental conditions, appears
not to be involved.
The inhibition of antihistamine-induced memory disrup-
tion disappeared 7 days after pretreatment with the
aODNs. This return of sensitivity implies both the total
reversal of aODN-induced specific inhibition of Gi expres-
sion and a lack of damage or toxicity associated with
aODN treatment. Pretreatment with the anti-Gi ODNs at
the highest effective doses did not modify the entrance
latency, showing the absence of any effect on memory
functions by these pretreatments. Therefore, the preven-
tion of diphenhydramine amnesia cannot be attributable to
a direct beneficial effect on memory processes induced by
the aODNs. Furthermore, the dODN did not modify diphen-
hydramine-induced amnesia in comparison with naive or
saline i.c.v. injected mice (data not shown). This observa-
tion ruled out the possibility that the antagonism exerted by
aODNs may have resulted from a sequence-independent
action on cerebral structures.
Diphenhydramine is a first-generation H1-receptor an-
tagonist (Simons and Simons, 1994). H1 receptors are
G-protein coupled receptors that activate phospholipase C
via a PTX-insensitive mechanism (Arrang, 1994). By con-
trast, the antagonism exerted by anti-Gi indicates that the
intracellular mechanism of analgesic action of the investi-
gated H1-antihistamine involves the activation of PTX-sen-
sitive G-proteins. It has been reported that first-generation
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Fig. 4. Lack of effect by pretreatment with an aODN to the  subunit of Go1- (25 g per mouse i.c.v.) and Go2- (25 g per mouse i.c.v.) protein gene
on diphenhydramine (20 mg kg1 s.c.), amnesia. Vertical lines represent S.E.M.; * P0.05, ** P0.01 in comparison with dODNsaline-treated mice.
0
1
2
3
4
5
6
0 15 30 45
dODN
anti-Gi
anti-Gi
anti-Gi
anti-Go
anti-Go
n
u
m
be
r o
f f
al
ls 
in
 3
0 
s
min
α1
α2
α3
α1
α2
Fig. 5. Effect of pretreatment with an aODN to the  subunit of Gi1-
(25 g per mouse i.c.v.), Gi2- (25 g per mouse i.c.v.), Gi3- (25 g per
mouse i.c.v.), Go1- (25 g per mouse i.c.v.) and Go2- (25 g per
mouse i.c.v.) protein gene on motor coordination in the mouse rota rod
test. Vertical lines represent S.E.M.
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H1-receptor antagonists are receptor-independent G-pro-
tein activators in HL-60 cells, basophils and mast cells and
that such a mechanism of action might be responsible for
the stimulatory effects of these compounds (Burde et al.,
1996). We can, therefore, suppose that a direct activation
of the Gi-protein-mediated transduction system might also
be responsible for the detrimental effect on memory func-
tions induced by antihistamines. The involvement of the
Gi-protein system has also been observed for other central
effects of antihistamines. Literature data evidenced that
diphenhydramine, pyrilamine and promethazine antinoci-
ception is prevented by the i.c.v. administration of PTX,
which inactivates Gi proteins (Galeotti et al., 1996, 1999)
and of aODNs against the  subunit of Gi proteins (Galeotti
et al., 2002). These results further support the hypothesis
of an involvement of the Gi protein-mediated system in the
intracellular events responsible for the induction of amne-
sia by diphenhydramine. However, first-generation H1-re-
ceptor antagonists induce histamine release from ba-
sophils and mast cells (Mota and Da Silva, 1960; Mota,
1966; Lichtenstein and Gillespie, 1975) and increase the
histamine levels in the cerebrospinal fluid (Suojaranta-
Ylinen et al., 1991). Since it is well known that histamine
can modulate the release of several neurotransmitters
(Hill, 1990), an involvement of neurotransmitters different
from histamine, activating Gi proteins as a signal transduc-
tion mechanism, downstream from the initial receptor in-
teraction, cannot be excluded.
In the present study we observed the lack of effect of
an aODN against Gi3 that implies that this subunit is not
a major component of transduction mechanisms leading to
amnesia. By contrast, other pharmacological activities of
diphenhydramine, as analgesia, are mediated by activa-
tion of the three Gi protein subtypes (Galeotti et al., 2002).
It is plausible to suppose that different-induced effects are
mediated by different Gi-protein subunits and that diphen-
hydramine could have different intrinsic activity for each
effect.
Taking into account present observations together with
several literature data, it appears that the Gi-protein sys-
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tem represents an essential intracellular step in the induc-
tion of amnesia. Gi proteins were shown to inhibit the
adenylyl cyclase activity with a consequent reduction of
intracellular cAMP levels (Wong et al., 1992). The role of
the cAMP cascade in memory processes has been re-
cently evidenced. Genetic and pharmacological studies in
mice and rats demonstrated that the cAMP responsive
element binding protein is required for a variety of complex
forms of memory, including spatial and social learning
(Silva et al., 1998). The activation of the cAMP-dependent
protein kinase induces long-term memory (Muller, 2000)
and the inhibition of cAMP phosphodiesterase reverses
memory deficits in the radial arm maze task (Zhang et al.,
2000). Several studies have also shown that the regulation
of adenylyl cyclase activity is disrupted in Alzheimer’s dis-
ease patients. The alteration of adenylyl cyclase activity in
postmortem brain is related to an impairment of the stim-
ulatory G-proteins (Gs) whereas the Gi-protein-mediated
inhibition of the enzyme is unaltered (Schnecko et al.,
1994; Fowler et al., 1995). Furthermore, lower Gs levels
and unmodified Gi levels were observed in fibroblasts
from familial Alzheimer’s disease patients (Shanahan et
al., 1997). Recently, it has been reported that amyloid
-peptides cause toxicity through activation of Gi proteins
(Soomets et al., 1999; Rymer and Good, 2001). We can
hypothesise that an intact Gi-protein functionality is essen-
tial for the induction of amnesia. Our results on diphenhy-
dramine amnesia confirm the hypothesis of a Gi-protein
involvement in the induction of memory impairment. By
considering that high cAMP levels are required for mne-
monic integrity, we can also suppose that diphenhydra-
mine induces amnesia through a reduction of intracellular
cAMP levels via the activation of Gi1 and Gi2 proteins.
As the Gi-proteins are widely distributed in the neural
areas, the function of a variety of cellular receptors is
expected to be altered by the impairing effect of the anti-
sense treatment. It has been, therefore, necessary to eval-
uate the possible induction of side effects by the anti-Gi
treatment. The aODNs, at the highest doses used, did not
modify animals’ gross behaviour. Moreover, additional be-
havioural tests were performed to illustrate any side effects
produced by the treatments that cannot be revealed by the
researcher through the observation of the animal’s spon-
taneous behaviour. The aODN treatment did not impair
motor coordination, as revealed by the progressive reduc-
tion of the number of falls in the rota rod test. Repetition of
the test session every 15 min progressively decreases the
number of falls since animals learn how to balance on the
rotating rod. The lack of variation, or an increase in the
number of falls after treatment indicates an impairment of
mice motor coordination that could lead to a misinterpre-
tation of the results obtained in the behavioural test. More-
over, aODNs did not modify spontaneous motility and ex-
ploratory activity as indicated by the hole board test. We
can, thus, suppose that the effects observed in the passive
avoidance test were not imputable to compromised behav-
ioural paradigms.
Similarly, the administration of histamine H1 receptor
antagonists produces various inhibitory effects including
sedation (Simons and Simons, 1994) whose appearance
could lead to a modification of the entrance latency values
observed in the passive avoidance test. At the dose em-
ployed, diphenhydramine exerted its amnesic activity with-
out showing any alteration of the mice motor coordination,
spontaneous motility and exploratory activity.
In conclusion, our results evidence that knockdown of
Gi1 and Gi2, but not by Gi3, Go1 and Go2, reversed
the diphenhydramine-induced amnesia, indicating the in-
volvement of this transduction system in the induction of a
detrimental effect on memory functions by
H1-antihistamines.
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